| Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity CIM Dahlberg, D Sarhan, M Chrobok, AD Duru, E Alici Frontiers in immunology 6, 605, 2015 | 97 | 2015 |
| Triticum durum metallothionein isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling K Bilecen, UH Ozturk, AD Duru, T Sutlu, MV Petoukhov, DI Svergun, ... Journal of Biological Chemistry 280 (14), 13701-13711, 2005 | 68 | 2005 |
| The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment K Uttervall, AD Duru, J Lund, J Liwing, G Gahrton, E Holmberg, J Aschan, ... PLoS One 9 (7), e101819, 2014 | 27 | 2014 |
| Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice P Brodin, T Lakshmikanth, R Mehr, MH Johansson, AD Duru, A Achour, ... PLoS One 5 (10), e13174, 2010 | 24 | 2010 |
| Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets E Kavak, A Najafov, N Ozturk, T Seker, K Cavusoglu, T Aslan, AD Duru, ... Cellular signalling 22 (10), 1523-1535, 2010 | 15 | 2010 |
| Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex C Madhurantakam, AD Duru, T Sandalova, JR Webb, A Achour PLoS One 7 (3), e32805, 2012 | 11 | 2012 |
| Re‐challenging with anti‐CD38 monotherapy in triple‐refractory multiple myeloma patients is a feasible and safe approach E Alici, M Chrobok, J Lund, T Ahmadi, I Khan, AD Duru, H Nahi British journal of haematology 174 (3), 473-477, 2016 | 10 | 2016 |
| Unexpected T‐cell recognition of an altered peptide ligand is driven by reversed thermodynamics EB Allerbring, AD Duru, H Uchtenhagen, C Madhurantakam, MB Tomek, ... European journal of immunology 42 (11), 2990-3000, 2012 | 10 | 2012 |
| The MHC Class I cancer-associated neoepitope Trh4 linked with impaired peptide processing induces a unique noncanonical TCR conformer I Hafstrand, EM Doorduijn, AD Duru, J Buratto, CC Oliveira, T Sandalova, ... The Journal of Immunology 196 (5), 2327-2334, 2016 | 7 | 2016 |
| Deletion of chromosomal region 8p21 confers resistance to Bortezomib and is associated with upregulated decoy TRAIL receptor expression in patients with multiple myeloma AD Duru, T Sutlu, A Wallblom, K Uttervall, J Lund, B Stellan, G Gahrton, ... PloS one 10 (9), e0138248, 2015 | 5 | 2015 |
| Autologous peripheral blood mononuclear cells as treatment in refractory acute respiratory distress syndrome P Jungebluth, B Holzgraefe, ML Lim, AD Duru, V Lundin, N Heldring, ... Respiration 90 (6), 481-492, 2015 | 5 | 2015 |
| The immunogenicity of a proline-substituted altered peptide ligand toward the cancer-associated TEIPP Neoepitope Trh4 is unrelated to complex stability I Hafstrand, EM Doorduijn, R Sun, A Talyzina, M Sluijter, S Pellegrino, ... The Journal of Immunology 200 (8), 2860-2868, 2018 | 3 | 2018 |
| Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity I Hafstrand, D Badia-Martinez, BJ Josey, M Norström, J Buratto, ... PloS one 12 (12), e0189584, 2017 | 1 | 2017 |
| Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin I Hafstrand, EC Sayitoglu, A Apavaloaei, BJ Josey, R Sun, X Han, ... Proceedings of the National Academy of Sciences 116 (11), 5055-5060, 2019 | | 2019 |
| Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells M Chrobok, CIM Dahlberg, EC Sayitoglu, V Beljanski, H Nahi, M Gilljam, ... Cancers 11 (1), 69, 2019 | | 2019 |
| Lenalidomide versus lenalidomide+ dexamethasone prolonged treatment after second‐line lenalidomide+ dexamethasone induction in multiple myeloma J Lund, A Gruber, B Lauri, AD Duru, C Blimark, A Swedin, M Hansson, ... Cancer medicine 7 (6), 2256-2268, 2018 | | 2018 |
| Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells EC Sayitoglu, D Ozkazanc, A Sarac, A Parlar, E Alici, B Erman, AD Duru, ... The Journal of Immunology 200 (1 Supplement), 169.19-169.19, 2018 | | 2018 |
| ESGCT XXV Anniversary Congress in Collaboration with the German Society for Gene Therapy October 17–20, 2017 Berlin, Germany SM Maffioletti, S Sarcar, A Henderson, I Mannhardt, L Pinton, LA Moyle, ... Human Gene Therapy 28 (12), A1-A125, 2017 | | 2017 |
| Optimized genetic modification of primary human NK cells AK Wagner, M Chrobok, A Hussain, M Gilljam, CIM Dahlberg, T Sutlu, ... SCANDINAVIAN JOURNAL OF IMMUNOLOGY 86 (4), 348-348, 2017 | | 2017 |
| Vaccination with proline-substituted neoepitope Trh4 generates enhanced CTL responses against tumors I Hafstrand, EM Doorduijn, AD Duru, R Sun, A Talyzina, M Sluijter, ... SCANDINAVIAN JOURNAL OF IMMUNOLOGY 86 (4), 346-346, 2017 | | 2017 |
Evren Alici, MD, PhDDepartment of Medicine, Karolinska InstitutetVerified email at ki.se